| Literature DB >> 31427638 |
Diego López-Guerra1, Jesús Santos-Naharro2, Adela Rojas-Holguín2, Isabel Jaen-Torrejimeno2, Aranzazu Prada-Villaverde2, Gerardo Blanco-Fernández2.
Abstract
Different topical products have been tested in liver resection to get a control of bleeding. This study compares the effectiveness and complications between two haemostatic agents Tachosil versus Hemopatch. A cohort study including patients who underwent liver resection since November 2014 to April 2016 was conducted. The study was performed in a single institution. Demographic variables, intraoperative characteristics and postoperative complications were analysed. A total of 92 patients (50 in Tachosil group and 42 in Hemopatch group) were included. No differences were found in patients who required intraoperative (Tachosil 6 (12%) vs Hemopatch 2 (4.8%); p = 0.28) and postoperative (Tachosil 4 (8%) vs Hemopatch 3 (7.1%); p = 0.87) blood transfusion. There were no differences in length of hospital stay (Tachosil 7.02 ± 4.1 days vs Hemopatch 7.63 ± 9.1; p = 0.67). Overall postoperative complications were similar between both patches (Tachosil 21 (42%) vs Hemopatch 14 (33%); p = 0.48). No differences were found in specific complications, however Hemopatch showed a higher incidence of intraabdominal abscess 5 (11.9%) and vs 0 (0%) p = 0.01.In this study no differences have been found between Hemopatch and Tachosil in the effectiveness and overall postoperative complication after liver resection, although Hemopatch shows a higher incidence of intraabdominal abscess. Further studies are necessary to confirm these findings.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31427638 PMCID: PMC6700165 DOI: 10.1038/s41598-019-48529-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart showing distribution in both hemostatic groups.
General Characteristics of patients.
| Characteristics | Tachosil (n = 50) | Hemopatch (n = 42) | P Value |
|---|---|---|---|
| Age, mean (SD*), y | 62.4 (13.4) | 61.4 (14.6) | 0.71 |
| Sex, male:female | 28:22 | 28:14 | 0.29 |
| ASA 1/2/3/4/5 | 2/28/18/2/0 | 3/27/12/0/0 | 0,43 |
| Preoperative Chemotherapy | 32 (64) | 16 (38,1) | 0,01 |
|
| |||
| Metastases No. (%) | 34 (68) | 18 (42.9) | 0.01 |
| Hepatocellular Carcinoma No. (%) | 3 (6) | 10 (23.8) | 0.01 |
| Cholangiocarcinoma No. (%) | 1 (2) | 2 (4.8) | 0.59 |
| Bening Diseases No. (%) | 8 (16) | 6 (14.3) | 0.82 |
| Others No. (%) | 4 (8) | 6 (14.3) | 0.50 |
*Standard deviation.
Intraoperative data of patients in Tachosil and Hemopatch group.
| Intraoperative data | Tachosil (n = 50) | Hemopatch (n = 42) | P Value |
|---|---|---|---|
| Intraoperative blood transfusión N° (%) | 6 (12) | 2 (4.8) | 0.28 |
| Intraoperative Blood Transfusion of PRBCa units, mean (SD*) | 2 (0.63) | 0.75 (0.95) | 0.03 |
|
| |||
| No Steatosis, No. (%) | 27 (54) | 21 (50) | 0.70 |
| Steatosis, No. (%) | 22 (44) | 15 (35.7) | 0.42 |
| Cirrhosis, No. (%) | 1 (2) | 6 (14.3) | 0.04 |
| Patients with Plingle clampling N°. (%) | 12 (24) | 11 (26.2) | 0.80 |
| Clampling time, mean (SD), min | 27 (14) | 24 (19) | 0.68 |
| Operating time, mean (SD), min | 202 (69) | 184 (55) | 0.16 |
apacked red blood cell.
*Standard deviation.
Postoperative data of patients in Tachosil and Hemopatch group.
| Postoperative data | Tachosil (n = 50) | Hemopatch (n = 42) | P Value |
|---|---|---|---|
| Length of Hospital Stay, mean (SD*), days | 7,02 (4,1) | 7,63 (9,1) | 0,67 |
| Drainage day Remove, mean (SD) | 4,4 (2,6) | 4,1 (1,9) | 0,54 |
| Postoperative blood transfusion No. (%) | 4 (8) | 3 (7,1) | 0,87 |
| Postoperative FFPa transfusion No. (%) | 0 (0) | 0 (0) | — |
| Postoperative Platelet transfusion No. (%) | 0 (0) | 0 (0) | — |
afresh frozen plasma.
*Standard deviation.
Figure 2Postoperative biochemical parameters at registered at day 1, 3 and 5. Values are mean in each postoperative day.
Postoperative complications of patients in Tachosil and Hemopatch group.
| Postoperative Complications | Tachosil (n = 50) | Hemopatch (n = 42) | P Value |
|---|---|---|---|
| Total Complications No. (%) | 21 (42) | 14 (33,3) | 0,48 |
| Grade I No. (%) | 14 (66,7) | 8 (57,1) | 0,31 |
| Grade II No. (%) | 5 (23,8) | 1 (7,1) | 0,21 |
| Grade III No. (%) | 1 (4,8) | 4 (28,6) | 0,17 |
| Grade IV No. (%) | 0 (0) | 0 (0) | — |
| Grade V No. (%) | 1 (4,8) | 1 (7,1) | >0,99 |
| Hemorrhage No. (%) | 0 (0) | 0 (0) | — |
| Bile Leakage No. (%) | 1 (2) | 2 (4,8) | 0,46 |
| Reoperation No. (%) | 1 (2) | 1 (2,4) | 0,90 |
| Intraabdominal Abscess No. (%) | 0 (0) | 5 (11,9) | 0,01 |
| Readmission No. (%) | 0 (0) | 4 (9,5) | 0,02 |